Genocea Biosciences Inc. buy tamam
Summary
This prediction ended on 04.03.19 with a price of €5.49. The BUY prediction by tamam for Genocea Biosciences Inc. performed very badly with a performance of -31.14%. tamam has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Genocea Biosciences Inc. | - | - | - | - |
iShares Core DAX® | -5.630% | -5.765% | 8.425% | 8.571% |
iShares Nasdaq 100 | -8.559% | -13.005% | 17.297% | 28.853% |
iShares Nikkei 225® | -9.576% | -9.058% | 3.827% | 0.117% |
iShares S&P 500 | -6.631% | -7.103% | 17.407% | 31.169% |
Comments by tamam for this prediction
In the thread Genocea Biosciences Inc. diskutieren
tamam stimmt der Buy-Einschätzung von stratec zu
tamam stimmt am 07.03.2018 der Buy-Einschätzung von stratec mit dem Kursziel 3$ zu.
Überschrift: Genocea : Cantor sees five-bagger potential